Founded in 2014, Intellia Therapeutics, Inc. is a leading biotechnology company at the forefront of the gene-editing revolution. Its mission is to develop and commercialize potentially curative medicines for severe and life-threatening diseases by precisely editing disease-associated genes in the human body. The company leverages the Nobel Prize-winning CRISPR/Cas9 technology platform for both *in vivo* (editing genes inside the body) and *ex vivo* (editing cells outside the body) therapies, targeting a range of genetic diseases. As a publicly traded entity, Intellia is a key player in advancing genomic medicine from research into clinical reality.

Founded in

United Kingdom